← Back to Search
A Clinical, Radiographic And Laboratory Evaluation Of Prognostic Factors In 363 Patients With Malignant Pleural Mesothelioma
A. C. Tanrıkulu, A. Abakay, M. A. Kaplan, M. Küçüköner, Y. Palancı, O. Evliyaoğlu, C. Sezgi, H. Şen, Ali İhsan Çarkanat, G. Kirbas
Published 2010 · Medicine
Save to my Library
Download PDFAnalyze on Scholarcy
Background: Malignant pleural mesothelioma (MPM) has a poor prognosis. Objectives: Only few studies in literature investigated the presence of pleural fluid and radiographic findings for the prognosis of MPM. Methods: We retrospectively investigated the hospital charts of 363 MPM patients who were diagnosed from January 1989 to March 2010. Survival time was calculated by the Kaplan-Meier method. Pretreatment clinical, laboratory and radiographic features of each patient at the time of diagnosis were obtained from patients’ charts. Results: The mean age of 363 patients (217 men, 146 women) was 50.6 ± 11.2 years (range 19–85) and the mean survival time was 11.7 ± 8.6 months (range 1–53). Histological types of MPM were epithelial (71.2%), mixed (15.9%) and sarcomatous type (4.9%). The frequency of disease stages were 31.4% for stage 1, 24.2% for stage 2, 28.6% for stage 3 and 15.8% for stage 4. The most frequent symptoms were dyspnea (82.1%), chest pain (68.3%) and weight loss (58.9%). Results of univariate and multivariate analyses revealed that a Karnofsky performance score ≤60, a pleural fluid glucose level ≤40 mg/dl, a C-reactive protein level >50 mg/l, a serum lactate dehydrogenase level >500 U/l, the presence of pleural fluid, pleural thickening >1 cm and a platelet count of >420 × 103/µl were found to be associated with poor prognosis in MPM. Conclusions: Our data suggest that low pleural fluid glucose and high C-reactive protein, the presence of pleural fluid and pleural thickening were associated with poor MPM prognosis. Further prospective studies are needed to highlight prognostic factors more clearly.
This paper references
Prognostic factors in malignant mesothelioma.
J. Burgers (2004)
Prognostic value of the serum tumour markers Cyfra 21-1 and tissue polypeptide antigen in malignant mesothelioma.
H. Schouwink (1999)
Mesothelioma and Asbestos-Related Pleural Diseases
L. Greillier (2008)
Biomarkers for mesothelioma
A. Scherpereel (2007)
Correlation of C-Reactive Protein with Survival and Radiographic Response to First-Line Platinum-Based Chemotherapy in Advanced Non-Small Cell Lung Cancer
S. Wilop (2008)
Incidence of Malignant Pleural Mesothelioma due to Environmental Asbestos Fiber Exposure in the Southeast of Turkey
A. Şenyiğit (2000)
Malignant pleural mesothelioma: CT manifestations in 50 cases.
A. Kawashima (1990)
Prognostic factors in patients with pleural mesothelioma: the European Organization for Research and Treatment of Cancer experience.
D. Curran (1998)
Prognostic factors of malignant mesothelioma of the pleura
V. de Pangher Manzini (1993)
vival of malignant pleural mesothelioma cases in the Tuscan Mesothelioma Register , 1988 – 2000 : a population - based study
G Gorini (2005)
Survival patterns for malignant mesothelioma: The seer experience
R. Spirtas (1988)
A. Moore (2008)
Assessment of environmental asbestos exposure in Turkey by bronchoalveolar lavage.
P. Dumortier (1998)
Malignant mesotheliomas diagnosed in Lower Normandy
M Letourneux (1980)
Prognostic factors for malignant mesothelioma in 142 patients: validation of CALGB and EORTC prognostic scoring systems
J. Edwards (2000)
Population based epidemiology and prognosis of mesothelioma in Leeds, UK
A. Chapman (2008)
Environmental malignant pleural mesothelioma in Southeast Turkey.
A. C. Tanrıkulu (2006)
Prognostic Significance of C-Reactive Protein and Smoking in Patients with Advanced Non-small Cell Lung Cancer Treated with First-Line Palliative Chemotherapy
A. Koch (2009)
Pleural fluid findings as prognostic factors for malignant pleural mesothelioma
T. Gonlugur (2008)
Diffuse Pleural Mesothelioma and Asbestos Exposure in the North Western Cape Province
Tim J. Carter (2005)
Pleural fluid analysis in malignant mesothelioma. Prognostic implications.
A. Gottehrer (1991)
The European mesothelioma epidemic
J. Peto (1999)
Survival of malignant pleural mesothelioma cases in the Tuscan Mesothelioma Register, 1988–2000: a population-based study
G. Gorini (2005)
Malignant mesothelioma: diagnostic and management strategies for 1992.
N. Vogelzang (1992)
A population based study
P. McIntyre (1993)
Pleuropneumonectomy in the management of diffuse malignant mesothelioma of the pleura. Experience with 29 patients.
E. Butchart (1976)
Prognostic factors of malignant mesothelioma of the pleura.
A. Anand (1994)
Malignant pleural mesothelioma due to environmental mineral fiber exposure in Turkey. Analysis of 135 cases.
Z. Selçuk (1992)
Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma.
N. Vogelzang (2003)
Prognostic factors in diffuse malignant pleural mesothelioma. A study of 167 patients.
E. Chailleux (1988)
Prognostic implications of normal (<0.10 ng/ml) and borderline (0.10 to 1.49 ng/ml) troponin elevation levels in critically ill patients without acute coronary syndrome.
Russell Stein (2008)
Malignant pleural mesothelioma: a disease unaffected by current therapeutic maneuvers.
A. Alberts (1988)
Malignant mesotheliomas diagnosed in Lower Normandy between 1980 and 1990
M Letourneux (1993)
Malignant Pleural Mesothelioma Caused by Environmental Exposure to Asbestos in the Southeast of Turkey: CT Findings in 117 Patients
A. Şenyiğit (2000)
Malignant pleural mesothelioma: clinicopathologic and survival characteristics in a consecutive series of 394 patients.
P. Borasio (2008)
Prognostic significance of flow cytometric DNA analysis in patients with malignant pleural mesothelioma.
S. Emri (2001)
Preoperative serum C-reactive protein level in non-small cell lung cancer.
M. Hara (2007)
Prognostic factors in diffuse malignant pleural mesothelioma: effects of pretreatment clinical and laboratory characteristics.
M. Metintas (2001)
Factors predictive of survival among 337 patients with mesothelioma treated between 1984 and 1994 by the Cancer and Leukemia Group B.
J. Herndon (1998)
Environmental fibrous zeolite (erionite) exposure and malignant tumors other than mesothelioma.
B. Baris (1996)
Survival of pleural malignant mesothelioma in Italy: A population‐based study
F. Montanaro (2009)
Computed tomography features in malignant pleural mesothelioma and other commonly seen pleural diseases.
M. Metintas (2002)
Multicenter phase II trial of neoadjuvant pemetrexed plus cisplatin followed by extrapleural pneumonectomy and radiation for malignant pleural mesothelioma.
L. Krug (2009)
Malignant pleural mesothelioma: some aspects of epidemiology, differential diagnosis and prognosis. Histological and immunohistochemical evaluation and follow-up of mesotheliomas diagnosed from 1964 to January 1985.
R. Walz (1990)
This paper is referenced by
Clinical and Pathologic Predictors of Clinical Outcome of Malignant Pleural Mesothelioma
R. Berardi (2016)
Prognostic factors influencing survival in 35 patients with malignant peritoneal mesothelioma.
H. Kaya (2014)
Malignant pleural mesothelioma : recognising an unmet need
Samal Gunatilake (2018)
DNA Methylation of FKBP5 as Predictor of Overall Survival in Malignant Pleural Mesothelioma
G. Cugliari (2020)
Clinicopathological features of patients with malignant mesothelioma in a multicenter, case-control study: no role for ABO-Rh blood groups.
G. Utkan (2013)
The role of imaging in malignant pleural mesothelioma: an update after the 2018 BTS guidelines.
S. Sinha (2020)
PLEASE, take a deep breath
J. M. Porcel (2020)
The influence of gemcitabine pathway polymorphisms on treatment outcome in patients with malignant mesothelioma
N. Erčulj (2012)
Nutrition, exercise, and complementary medicine: potential role in mesothelioma?
S. Muruganandan (2016)
Prognostic nutritional index predicts outcomes of malignant pleural mesothelioma
Zhou-Hong Yao (2013)
KRAS signalling in malignant pleural mesothelioma
A. Marazioti (2020)
Systemic inflammation in malignant pleural mesothelioma: Is neutrophyl-to-lymphocyte ratio a prognostic index?
Felice Mucilli (2016)
Supplementary Prognostic Variables for Pleural Mesothelioma
H. Pass (2014)
Validation of prognostic factors in malignant pleural mesothelioma: a retrospective analysis of data from patients seeking compensation from the New South Wales Dust Diseases Board.
S. Kao (2013)
Malign Plevral Mezotelyoma prognozunda yeni bir inflamatuar parametrenin değeri
Çetin Tanrıkulu (2013)
Clinical and Radiologic Features
A. Roden (2015)
Prognostic value of the lymphocyte-to-monocyte ratio and other inflammatory markers in malignant pleural mesothelioma
A. C. Tanrıkulu (2016)
Transcriptional over-expression of chloride intracellular channels 3 and 4 in malignant pleural mesothelioma
V. Tasiopoulou (2015)
Inflammation in malignant mesothelioma - friend or foe?
Anthony Linton (2012)
Malignant pleural mesothelioma presenting as acute empyema with severe leukocytosis.
K. Matsuoka (2014)
Fibulin-3 as a diagnostic biomarker in patients with malignant mesothelioma.
H. Kaya (2015)
Prognostic factors in malignant pleural mesothelioma: a retrospective study of 60 Turkish patients.
A. Koyuncu (2015)
Asbestos-the Silent Killer: a review of screening and diagnostic imaging of asbestos related lung disease
Ali Khan (2011)
Rapidly progressive sarcomatoid malignant mesothelioma of the pleura mimicking pulmonary empyema
K. Fujita (2015)
DNA Repair Polymorphisms and Treatment Outcomes of Patients with Malignant Mesothelioma Treated with Gemcitabine-Platinum Combination Chemotherapy
N. Erčulj (2012)
Pretreatment Serum C-Reactive Protein Levels Predict Benefit From Multimodality Treatment Including Radical Surgery in Malignant Pleural Mesothelioma: A Retrospective Multicenter Analysis
B. Ghanim (2012)
High-risk mesothelioma relation to meteorological and geological condition and distance from naturally occurring asbestos
A. Abakay (2015)
The Prevalence and Clinical Relevance of Non-expandable Lung in Malignant Pleural Mesothelioma: A Prospective, Single-Center Cohort Study of 229 Patients.
A. Bibby (2019)
Myeloid-derived interleukin-1β drives oncogenic KRAS-NF-κΒ addiction in malignant pleural effusion
A. Marazioti (2018)
Clinical and biologic prognostic factors in malignant pleural mesothelioma
V. Ambrogi (2012)
A new prognostic index for overall survival in malignant pleural mesothelioma: the rPHS (regimen, PS, histology or stage) index.
Yuki Kataoka (2015)
Malignant pleural mesothelioma: factors influencing the prognosis.
T. Mineo (2012)See more